Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07291323Early Phase 1Recruiting

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

Role: lead

NCT07545811Phase 1Recruiting

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT05519449Phase 1Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Role: lead

NCT05783622Phase 1Recruiting

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Role: lead

All 4 trials loaded